About 1,848,886 results (3,113 milliseconds)

Precision Medicine Takes Center Stage in GI Cancer

https://news.google.com/__i/rss/rd/articles/CBMiXWh0dHBzOi8vd3d3LmNhbmNlcm5ldHdvcmsuY29tL3ZpZXcvam91cm5hbC1wcmVjaXNpb24tbWVkaWNpbmUtdGFrZXMtY2VudGVyLXN0YWdlLWluLWdpLWNhbmNlctIBAA?oc=5
Mar 19, 2021 ... ... Breast Cancer After Pathological Complete Response to Neoadjuvant Chemotherapy ... the recommended phase 2 dose (RP2D) of fruquintinib. Any ...

Long-Term Metformin Use Linked to Fewer ER+ Breast Cancers

https://news.google.com/__i/rss/rd/articles/CBMiK2h0dHBzOi8vd3d3Lm1lZHNjYXBlLmNvbS92aWV3YXJ0aWNsZS85NDUxNzTSAQA?oc=5
Feb 3, 2021 ... "The report by Park adds to the growing evidence linking type 2 diabetes and its treatment to breast cancer risk but definitive conclusions ...

Outcomes in TN Breast Cancer Predicted by Blood Biomarkers

https://news.google.com/articles/CBMiK2h0dHBzOi8vd3d3Lm1lZHNjYXBlLmNvbS92aWV3YXJ0aWNsZS85MjI3MDDSAQA?hl=en-ET&gl=ET&ceid=ET%3Aen
Dec 16, 2019 ... ... breast cancer will have a better outcome at 2 years and which will do much worse, a phase 2 randomized controlled trial indicates. "What we ...

Updates From ASCO 2021 for HER2+ Breast Cancer

https://news.google.com/__i/rss/rd/articles/CBMiUGh0dHBzOi8vd3d3LmNhbmNlcm5ldHdvcmsuY29tL3ZpZXcvdXBkYXRlcy1mcm9tLWFzY28tMjAyMS1mb3ItaGVyMi1icmVhc3QtY2FuY2Vy0gEA?oc=5
Jul 22, 2021 ... ... would allow me to give her endocrine therapy and dual HER2-targeted therapy. There was a randomized phase 2 study from the group in China ...

Breast cancer treatment can be safely reduced in women over the ...

http://feedproxy.google.com/~r/google/qxvx/~3/rthU8BoQZAY/url
Apr 16, 2021 ... "However, we have found that overtreatment of early-stage breast cancer in older patients may actually cause harm while not improving recurrence ...

Antibody-Drug Conjugates as an Adjuvant Therapy for Human ...

https://news.google.com/__i/rss/rd/articles/CBMiMWh0dHBzOi8vYXNjb3B1YnMub3JnL2RvaS9hYnMvMTAuMTIwMC9KQ08uMjIuMDAxMzXSAQA?oc=5
Apr 14, 2022 ... Antibody-Drug Conjugates as an Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer. The following ...

Antibody-Drug Conjugates as an Adjuvant Therapy for Human ...

https://news.google.com/__i/rss/rd/articles/CBMiMWh0dHBzOi8vYXNjb3B1YnMub3JnL2RvaS9hYnMvMTAuMTIwMC9KQ08uMjIuMDAxMzXSAQA?oc=5
Apr 14, 2022 ... Antibody-Drug Conjugates as an Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer. The following ...

First clinical trial on HER-2-negative breast cancer with nintedanib ...

http://feedproxy.google.com/~r/sciencedaily/top_news/top_health/~3/2uR8j3UkOtQ/140910120424.htm?utm_source=feedburner&utm_medium=email
Sep 10, 2014 ... The experimental drug nintedanib, combined with standard chemotherapy with paclitaxel, causes a total remission of tumors in 50 percent of ...

Dr. Mascarenhas on Updates from the MANIFEST Trial in ...

https://news.google.com/__i/rss/rd/articles/CBMiX2h0dHBzOi8vd3d3Lm9uY2xpdmUuY29tL3ZpZXcvZHItbWFzY2FyZW5oYXMtb24tdXBkYXRlcy1mcm9tLXRoZS1tYW5pZmVzdC10cmlhbC1pbi1teWVsb2ZpYnJvc2lz0gEA?oc=5
Jun 11, 2022 ... Although early-stage HER2-positive breast cancer remains a highly heterogeneous disease, its evolving treatment paradigm of tailored approaches ...